Hazard
297 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.
Of the 297 degradation recalls we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 47 (16%) are Severe.
Which agencies issued them
Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all degradation recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.
A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.
Boehringer Ingelheim Roxane Inc. is recalling 5,364 bottles of Calcitriol Oral Solution 1 mcg/mL due to a failed impurity specification.
Teva Pharmaceuticals is recalling 9,882 bottles of Dextroamphetamine Sulfate 10 mg tablets because stability testing revealed out-of-specification impurities.
Teva Pharmaceuticals is recalling 17,181 bottles of 2 mg Buprenorphine Hydrochloride Sublingual Tablets because stability testing revealed high out-of-specification impurity levels.
Teva Pharmaceuticals is recalling 53,452 bottles of 8 mg Buprenorphine Hydrochloride sublingual tablets because stability testing revealed high out-of-specification impurity levels.
Lupin Pharmaceuticals is recalling specific lots of Suprax Cefixime for Oral Suspension because the product failed impurity specifications at the 9-month stability station.
Lupin Pharmaceuticals is recalling 4,038 bottles of Suprax Cefixime for Oral Suspension because the product failed impurity specifications at the 9-month stability station.
Fougera Pharmaceuticals is recalling 31,122 tubes of Ketoconazole Cream 2% because of out-of-specification degradant results.
Lupin Pharmaceuticals is recalling Quinapril 10 mg tablets because stability testing revealed an unknown impurity above specification limits.
Pfizer is recalling specific lots of Zithromax (azithromycin) injection due to out-of-specification results for a degradant.
Fresenius Kabi USA is recalling folic acid injection vials due to failed impurity and degradation specifications at 14 and 15 months.
VistaPharm is recalling Nystatin Oral Suspension because it failed impurity and degradation specifications. The affected product is distributed nationwide.
West-Ward Pharmaceutical Corp. is recalling 51,704 bottles of Lisinopril Tablets, USP, 2.5 mg because they failed impurity specifications at the 48-month time point.
Warner Chilcott US LLC is recalling 188,600 bottles of Enablex (darifenacin) 15 mg extended-release tablets because they failed impurity specifications.
Actavis South Atlantic LLC is recalling 133,968 bottles of Ranitidine Syrup because the product failed an impurity specification for 'Related Compound C'.
Teva Pharmaceuticals is recalling Errin (norethindrone) tablets because an impurity called N-Butyl-Benzene Sulfonamide was detected during testing.
Fresenius Kabi USA is recalling 80,480 vials of Folic Acid Injection due to failed impurities and degradation specifications.
Actavis is recalling Fentanyl Transdermal Systems, 50 mcg/h, because they failed impurities and degradation specifications.
Fougera Pharmaceuticals is voluntarily recalling 60,210 units of Ketoconazole Cream 2% because an unknown degradant failed impurity specifications.
Watson Laboratories is recalling meprobamate 200 mg tablets because an impurity, diphenyl sulfone, exceeded specification limits.
Schering-Plough is recalling 17,169 packages of Temodar (temozolomide) 20 mg capsules due to out-of-specification degradation product testing results.
Actavis Mid Atlantic LLC is recalling Prometh VC Plain bottles because they do not meet stability specifications for an unknown degradant.
Teva Pharmaceuticals is recalling specific lots of Zeosa chewable oral contraceptive tablets because they may not meet impurity specifications.